Posted by Michael Wonder on 20 May 2022
FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder
20 May 2022 - Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis in adults and paediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds).
Today’s action marks the first FDA approval of a treatment for eosinophilic esophagitis.
